TY - JOUR
T1 - Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders
AU - Baldwin, Christina
AU - Zerofsky, Melissa
AU - Sathe, Meghana
AU - Troendle, David M.
AU - Perito, Emily R.
N1 - Funding Information:
From the *Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Texas Southwestern, Dallas, TX; and †Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Francisco, San Francisco, CA. Received for publication December 21, 2018; accepted May 16, 2019. Address correspondence to: Emily R. Perito, MD, Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Francisco, 550 16th St, 5th Floor, Box 0136, San Francisco, CA 94143 (e‐mail: emily.perito@ucsf.edu). This work is supported by the National Institute of Health (NIH)– National Institute of Diabetes and Digestive and Kidney Diseases K23 (DK0990253-A101 [E.R.P.]), NIH–National Institute of Diabetes and Digestive and Kidney Diseases U01 (DK108328-02S1 [D.M.T.]), and the Cystic Fibrosis Foundation. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the NIH or the Cystic Fibrosis Foundation. These data were presented previously as a poster at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition 2018 meeting. The authors declare no conflict of interest. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001350
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Objectives Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD). Methods Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD. Results Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had ≥1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%). Conclusions Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.
AB - Objectives Recurrent pancreatitis is considered a rare manifestation of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction; this case series highlights that pancreatitis can be a presenting symptoms of cystic fibrosis (CF) or a CFTR-related disorder (CFTR-RD). Methods Retrospective review of patients younger than 30 years diagnosed as having acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) and subsequently diagnosed as having CF or CFTR-RD. Results Among 18 patients, median time from diagnosis of ARP/CP to diagnosis of CF was 0.4 years (range, 0-33 years). Eight were classified as having CF by elevated sweat chloride testing (SCT). Five had intermediate SCT (30-59 mmol/L) with 2 pathogenic mutations. Five had CFTR-RD with intermediate SCT and 0 to 1 pathogenic mutations. Eight patients (44%) had exocrine pancreatic insufficiency, and pancreatic fluid collections were more common in this group. Based on the CFTR mutation, 6 patients were eligible for CFTR potentiator therapy, although none received it during the study period. Nine of the 18 had ≥1 other likely CF manifestations, including sinusitis (33%), nasal polyps (11%), pneumonia (22%), and gallbladder disease (22%). Conclusions Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.
KW - CFTR-related disorder
KW - acute recurrent pancreatitis
KW - chronic pancreatitis
KW - cystic fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85069457775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069457775&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001350
DO - 10.1097/MPA.0000000000001350
M3 - Article
C2 - 31268981
AN - SCOPUS:85069457775
SN - 0885-3177
VL - 48
SP - 888
EP - 893
JO - Pancreas
JF - Pancreas
IS - 7
ER -